Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harkleroad, L. E.
Right arrow Articles by Lordon, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harkleroad, L. E.
Right arrow Articles by Lordon, R. E.

Chest, Vol 82, 84-87, Copyright © 1982 by American College of Chest Physicians

ARTICLES

Pulmonary sarcoidosis. Long-term follow-up of the effects of steroid therapy

LE Harkleroad, RL Young, PJ Savage, DW Jenkins and RE Lordon

Fifteen years ago we began a prospective study using alternate case treatment with prednisone in patients with pulmonary function abnormalities due to sarcoidosis. Twenty-five patients were divided into treatment and control groups that were similar in sex, age, race, degree of pulmonary dysfunction, and duration of disease. Evaluation included complete spirometric studies, single-breath carbon monoxide diffusion capacity, and arterial blood gases. Follow-up studies at six months, one to two years, and ten to 15 years show no difference between the treated and untreated groups. Improvement or deterioration in pulmonary function of individual patients in the treated group was reflected in the control group, even in those patients with a diffusing capacity and forced vital capacity less than 65 percent of predicted. Data from this long-term study fail to show any benefit of short-term use of steroids in therapy for pulmonary sarcoidosis.


This article has been cited by other articles:


Home page
 ChestHome page
J. M. Reich
What Is Sarcoidosis?
Chest, July 1, 2003; 124(1): 367 - 371.
[Full Text] [PDF]

Home page
 ChestHome page
A. Pietinalho, P. Tukiainen, T. Haahtela, T. Persson, and O. Selroos
Early Treatment of Stage II Sarcoidosis Improves 5-Year Pulmonary Function
Chest, January 1, 2002; 121(1): 24 - 31.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. A. Judson and R. Uflacker
Treatment of a Solitary Pulmonary Sarcoidosis Mass by CT-Guided Direct Intralesional Injection of Corticosteroid
Chest, July 1, 2001; 120(1): 316 - 317.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
G J GIBSON
Sarcoidosis: old and new treatments
Thorax, May 1, 2001; 56(5): 336 - 339.
[Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
G. Hunninghake
Statement on Sarcoidosis
Am. J. Respir. Crit. Care Med., August 1, 1999; 160(2): 736 - 755.
[Full Text]

Home page
 ThoraxHome page
D. M Mitchell and A. Woodcock
Introduction
Thorax, August 1, 1999; 54(90002): S1 - 1.
[PDF]

Home page
 ChestHome page
M. A. Judson
An Approach to the Treatment of Pulmonary Sarcoidosis With Corticosteroids: The Six Phases of Treatment
Chest, April 1, 1999; 115(4): 1158 - 1165.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
B. T. SOCIETY and S. O. C. COMMITTEE
The Diagnosis, Assessment and Treatment of Diffuse Parenchymal Lung Disease in Adults---British Thoracic Society recommendations
Thorax, April 1, 1990; 54(90001): 1S - 28.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1982 by the American College of Chest Physicians.